BofA raised the firm’s price target on Johnson & Johnson to $254 from $253 and keeps a Neutral rating on the shares following what the firm calls “an okay 1Q print” that “offered nothing thesis changing.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $283 from $267 at Morgan Stanley
- Johnson & Johnson price target raised to $265 from $255 at RBC Capital
- Protagonist Therapeutics price target raised to $121 from $110 at Truist
- Johnson & Johnson price target raised to $250 from $220 at Stifel
- Johnson & Johnson price target raised to $255 from $234 at Barclays